Regeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License Application
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:…
DIAGNOS Provides Update on its Health Canada Medical Device Licence Application
BROSSARD, Quebec, April 09, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or…
Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order
March 31, 2025 20:10 ET | Source: Avicanna Inc. Auditor Licensing &…
KuCoin EU Files MiCAR Application in Austria to Ensure Compliant EEA Operations
Key Takeaways: KuCoin EU Exchange GmbH ("KuCoin EU") is applying for a…
VCTI Launches BEAD Application Service to Help Broadband Providers Secure Funding Faster with Higher Business Case Accuracy
BEAD Resource Center Launches on VCTI Website SOMERSET, N.J., Feb. 5, 2025…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4…
Adam Ferrari Health Science Scholarship Application Window Closes
January 10, 2025 10:30 ET | Source: The Ferrari Foundation DENVER, Jan.…
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Back to media releasesNext media release LONDON, Jan. 7, 2025 /PRNewswire/ --…